Compare BTGO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTGO | ALLO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.1M | 452.6M |
| IPO Year | 2025 | 2018 |
| Metric | BTGO | ALLO |
|---|---|---|
| Price | $3.40 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $8.88 | ★ $9.00 |
| AVG Volume (30 Days) | 1.1M | ★ 11.4M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.14 | $180.53 |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.48 | $0.65 |
| 52 Week High | $15.30 | $4.46 |
| Indicator | BTGO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 24.00 | 17.76 |
| Support Level | N/A | N/A |
| Resistance Level | $5.72 | $2.22 |
| Average True Range (ATR) | 0.39 | 0.09 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 2.60 | 0.05 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).